Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Change in peak early diastolic strain rate measured by cardiac MRI
研究概览
简要总结
There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors. Both of these therapies target the incretin system using different methods to elevate/maintain circulating levels of GLP1 to subsequently achieve improved blood sugar control. Interestingly, GLP1 analogues have been reported not only to improve blood sugar control but to additionally induce weight-loss and emerging experimental evidence has shown it may have beneficial effects on the heart's structure and function. Due to the profile of this condition being a lot worse and younger patients having greater CVD risk, a therapy offering multiple positive effects, in particular the potential cardiometabolic effects, make this line of therapy attractive in this patient population.
The aim of this research is to investigate the cardiometabolic effects of Liraglutide (GLP1 analogue) compared to that of its clinically relevant comparator Sitagliptin (DPP IV inhibitor).
详细描述
T2DM in the young
T2DM has traditionally been associated with older age, with type 1 diabetes (T1DM) being the dominant form in younger populations. This traditional profile has dramatically altered over the last couple of decades; the sharp rise in levels of obesity and sedentary lifestyles witnessed in younger age groups in developed countries has resulted in up to a 10 fold increase in the prevalence of T2DM in younger adults and youth [7]. Whereas T2DM was once a rarity in those under 40 years, we have recently shown that T2DM now represents up to 20% of all registered diabetes cases across centres in Leicester and Sheffield in this age group [8]. More worryingly, sub-analysis of the Leicester arm of the international ADDITION study [9], a large population-based screening study that included a small cohort under 40 years of age (n = 445), and an on-going NPRI-MRC study in younger high risk adults, suggest the prevalence of undiagnosed T2DM in those under 40 years is between 2 to 4% depending on the diagnostic criteria used and over 5% in those with a family history or obesity (unreported observations). The focus of health care policy and research has lagged behind this substantive shift in the profile of T2DM towards younger populations. For example, the NHS health checks programme is targeted at those over 40 years of age while previous self-management, lifestyle and pharmaceutical interventions which have been used to inform NICE guidance have been conducted in groups aged between 50 and 70 years.
Clinical Burden of T2DM in the young
The onset of T2DM in younger adults and youth represents an extreme phenotype that magnifies the disease profile observed in older adults. For example, those diagnosed with T2DM under 40 years are more likely to be classified with Class II or Class III obesity (≥35 kg/m2), have a multigenerational family history of T2DM, lead a sedentary lifestyle and be of minority ethnic origin [7]. Of particular concern is that the onset of T2DM in younger adults is associated with dramatic elevations in the risk of cardiovascular disease, particularly coronary heart disease. For example, the risk of any macrovascular complication in younger adults with T2DM compared to controls has been shown to be twice as high compared to other T2DM patients (HR 7.9 vs. 3.8, respectively)[10]. Myocardial infarction (MI) was found to be the most common macrovascular outcome; the hazard of developing an MI in younger adults with T2DM was 14-fold higher than in control subjects [10]. In contrast, older adults with T2DM had less than four times the risk of developing an MI compared with control subjects. Others have reported that the mortality rate in young people with T2DM was as high as 9% over a 9 year period [11]. Younger people with T2DM therefore have higher complication rates than their peers with Type 1 diabetes, despite a shorter duration of diabetes, highlighting the aggressive nature of the disease.
Our group has recently completed a Medical Research Council (MRC) funded study aimed at elucidating the biochemical and cardiac abnormalities associated with T2DM in younger adults (18 to 40 years). The study recruited 20 young adults (18 to 40 years) with diagnosed T2DM and 20 age-matched metabolically healthy obese and lean controls (paper under preparation). Cardiac structure and function were assessed by state-of-the-art tagged cardiac MRI imaging. The most striking finding from this study was evidence of greater diastolic dysfunction in T2DM compared to both the obese and lean controls. Specifically, peak end diastolic strain rate, a highly sensitive measure of left ventricular (LV) diastolic function, had an average value of 1.27 s-1 in the T2DM cohort (the lower limit of normal ranges has been defined as 1.3 s-1) which was 20% lower than the obese controls and 30% lower than the lean controls. This finding is consistent with a larger study that used echocardiography to assess cardiac function and structure in over 150 adolescents and younger adults with T2DM compared to obese and lean controls; this study reported that diastolic dysfunction was reduced from lean to obese and from obese to T2DM. These studies therefore suggest that pre-clinical diastolic dysfunction is already manifest in younger adults with T2DM, despite their relatively young age and short duration of type 2 diabetes. This finding is highly clinically relevant and suggests that the high risk of cardiovascular disease observed in T2DM is predominantly characterised by diastolic dysfunction predisposing these patients to heart failure, in advance of overt systolic compromise [12,13]. For example, 50% of all cases of chronic heart failure have preserved ejection fraction [12,13]. Therefore therapeutic strategies that target both glycaemic control and diastolic cardiac function would be highly desirable in younger adults with T2DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capacity to provide informed consent before any trial-related activities
- •Individuals aged 18 - 60 years inclusive
- •Established T2DM
- •BMI ≥ 30 kg/m2 (≥27 kg/m2 for South Asians or other BME populations)
- •On mono or combination oral OAD therapy (sulphonylurea and/or metformin) for ≥ 3months
- •No prescribed thiazolidinediones within the last 3 months
- •An HbA1c value of greater than or equal to 6.5% and less than 10%
排除标准
- •< 18 years old
- •Absolute contraindications to MRI
- •Type 1 diabetes (identified through C-peptide analysis)
- •Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
- •Suffer from terminal illness
- •Have impaired renal function (eGFR < 30 ml/min/1.73m2) )
- •Impaired liver function (ALAT≥2.5 times upper limit of normal)
- •Known to be Hepatitis B antigen or Hepatitis C antibody positive
- •Clinically significant active cardiovascular disease including history of myocardial infarction within the past 6 months and/or heart failure (NYHA class III and IV) at the discretion of the investigator
- •Recurrent major hypoglycaemia as judged by the investigator
- •Known or suspected allergy to the trial products
- •Known or suspected thyroid disease
- •Receipt of any investigational drug within four weeks prior to this trial
- •Have severe and enduring mental health problems
- •Are not primarily responsible for their own care
- •Are receiving insulin therapy
- •Have taken a thiazolidinedione within the last 3 months
- •Any contraindication to Sitagliptin or Liraglutide
- •Have severe irritable bowel disorder
- •Have pancreatitis or a previous history of pancreatitis
研究组 & 干预措施
Liraglutide
Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
干预措施: Liraglutide (Drug)
Sitagliptin
Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
干预措施: Sitagliptin (Drug)
结局指标
主要结局
Change in peak early diastolic strain rate measured by cardiac MRI
时间窗: Change from baseline peak end diastolic strain rate at 26 weeks
It is now well recognised that diastolic dysfunction is the primary characteristic of heart disease in T2DM. Measured by gold-standard tagged cardiac MRI. MRI scans will be anonymised and sent to a stand-alone work station for independent analysis.
次要结局
- Composite of standard biochemical variables(Changes from baseline to 26 weeks)
- Composite chronic low-grade inflammation and adiposity(Changes from baseline to 26 weeks)
- Composite Endothelial Function(Changes from Baseline to 26 weeks)
- Composite Quality of Life and Depression(Changes from baseline to 26 weeks)
- Composite Outcomes(Post-26 week analysis)
- Composite 7 point glucose profile(Chanegs from baseline to 26 weeks)
- Composite Medication Usage(Changes from Baseline to 26 weeks)
- Composite Hypoglycemic Episodes(Changes from baseline to 26 weeks)
- Composite Standard Anthropometric variables(Changes from baseline to 26 weeks)
- MRI defined adiposity(Changes from baseline to 26 weeks)
- Composite Lifestyle variables(Changes from baseline to 26 weeks)
- Composite treatment and satisfaction(Changes from Baseline to 26 weeks)
- Composite MRI Outcomes(Change from baseline cardiac measures at 26 weeks)
